SEC Comment Letter 0000000000-23-009862 to Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310) (TSHA)
Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310)
Date: Sept. 6, 2023 · CIK: 0001806310 · Accession: 0000000000-23-009862
AI Filing Summary & Sentiment
File numbers found in text: 333-274264
Letter
United States securities and exchange commission logo September 6, 2023 Sean P. Nolan Chief Executive Officer Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas, TX 75247 Re:Taysha Gene Therapies, Inc. Registration Statement on Form S-3 Filed August 30, 2023 File No. 333-274264 Dear Sean P. Nolan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Madison Jones, Esq.
Show Raw Text
United States securities and exchange commission logo
September 6, 2023
Sean P. Nolan
Chief Executive Officer
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas, TX 75247
Re:Taysha Gene Therapies, Inc.
Registration Statement on Form S-3
Filed August 30, 2023
File No. 333-274264
Dear Sean P. Nolan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Madison Jones, Esq.